Addiction Labs of America, LLC

Addiction Labs of America, LLC was paid $141K by Medicaid between Sep 2018 and Dec 2021, across 4 billing codes. Its largest line is U0003, Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r — 87% of everything it billed.

33Billing provider infoADDICTION LABS OF AMERICA, LLC
BRENTWOOD, TN 37027

33aNPI1639502255assigned 08/19/2013

33bProvider typeClinical Medical Laboratory

28Total paid$141K

24GClaims2,817

24DCodes billed4

24AFirst – last monthSep 2018 – Dec 2021

Compared with peers

Next to other Clinical Medical Laboratory providers in Tennessee

Rank by total paid#36 of 70

Median peer was paid$141K

This provider vs. median1.0×

Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.

Box 24A · Dates of service

Paid by month

Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider

By year, as a table

Year	Claims	Paid
2018	142	$862.82
2019	79	$200.74
2020	704	$45K
2021	1,892	$95K

Box 24 · Service lines

What it billed for

Code	Service	Share	Claims	Bene. records	Paid
U0003	Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r	87%	1,686	1,264	$122K
U0005	Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2	13%	910	641	$18K
G0480	Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed	<1%	118	84	$1K
80307	Drug test(s), presumptive, any number of drug classes; immunoassay	<1%	103	67	$59.86

Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.

From NPPES

Who's on the registration

Authorized officialCALARCO, MARK (FACILITY CEO)

Same official

Other billing entities under CALARCO, MARK

Full network →

Provider	Location	Paid
Las Vegas Professional Group - Calarco, P. C.	Las Vegas, NV	$1K

Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.